X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the license agreement between Roche and Chugai, Chugai obtained commercialization rights in Japan for ALN-AGT01 (zilebesiran), an RNAi therapeutic targeting angiotensinogen, for hypertension with high cardiovascular risk.
Lead Product(s): Zilebesiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 19, 2024
Details:
ALN-AGT01 (zilebesiran) investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen in development for the treatment of hypertension in high unmet need populations.
Lead Product(s): Zilebesiran,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
ALN-AGT01 (zilebesiran) is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen. It is being evaluated in combination with standard of care for the treatment of hypertension.
Lead Product(s): Zilebesiran,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
ALN-AGT01 (zilebesiran), is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen (AGT) in development for the treatment of hypertension in high unmet need populations.
Lead Product(s): Zilebesiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Under the partnership, Roche and Alnylam will co-develop and co-commercialise RNAi therapeutic ALN-AGT01 (zilebesiran), an investigational RNAi therapeutic currently in Phase 2 for the treat hypertension in patients with high cardiovascular risk.
Lead Product(s): Zilebesiran,Olmesartan Medoxomil
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $310.0 million
Deal Type: Partnership July 24, 2023
Details:
Across various cohorts in the Phase 1 study, zilebesiran was shown to be generally well tolerated with an acceptable safety profile that supports continued development.
Lead Product(s): Zilebesiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
